 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1992 | 2 | 0 | 2 | | 1994 | 1 | 1 | 2 | | 1996 | 2 | 2 | 4 | | 1997 | 1 | 5 | 6 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 4 | 4 | | 2000 | 1 | 5 | 6 | | 2001 | 3 | 4 | 7 | | 2002 | 1 | 2 | 3 | | 2003 | 1 | 4 | 5 | | 2004 | 1 | 5 | 6 | | 2005 | 3 | 2 | 5 | | 2006 | 3 | 2 | 5 | | 2007 | 4 | 6 | 10 | | 2008 | 3 | 7 | 10 | | 2009 | 3 | 8 | 11 | | 2010 | 2 | 2 | 4 | | 2011 | 2 | 8 | 10 | | 2012 | 5 | 9 | 14 | | 2013 | 7 | 8 | 15 | | 2014 | 10 | 10 | 20 | | 2015 | 10 | 7 | 17 | | 2016 | 6 | 1 | 7 | | 2017 | 7 | 6 | 13 | | 2018 | 6 | 2 | 8 | | 2019 | 7 | 7 | 14 | | 2020 | 1 | 2 | 3 | | 2021 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 08 26; 385(9):815-825.
-
Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 06 15; 203(12):1522-1532.
-
Alexeev EE, Dowdell AS, Henen MA, Lanis JM, Lee JS, Cartwright IM, Schaefer REM, Ornelas A, Onyiah JC, Vögeli B, Colgan SP. Microbial-derived indoles inhibit neutrophil myeloperoxidase to diminish bystander tissue damage. FASEB J. 2021 05; 35(5):e21552.
-
Rudolph J, Roberts G, Luger K. Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs. Nat Commun. 2021 02 02; 12(1):736.
-
Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 02 01; 203(3):381-385.
-
Pasupneti S, Tian W, Tu AB, Dahms P, Granucci E, Gandjeva A, Xiang M, Butcher EC, Semenza GL, Tuder RM, Jiang X, Nicolls MR. Endothelial HIF-2a as a Key Endogenous Mediator Preventing Emphysema. Am J Respir Crit Care Med. 2020 10 01; 202(7):983-995.
-
Bratcher PE, Yadav S, Shaughnessy CA, Thornell IM, Zeitlin PL. Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Physiol Rep. 2020 10; 8(19):e14603.
-
Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020 06; 55(6).
-
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020 05; 8(5):453-460.
-
Le Cras TD, Abman SH. Early Disruption of VEGF Receptor Signaling and the Risk for Adult Emphysema. Am J Respir Crit Care Med. 2020 03 01; 201(5):620-621.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|